Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Emerging evidence suggests that a small subpopulation of cancer stem cells (CSCs) is responsible for initiation, progression, and metastasis cascade in tumors. CSCs share characteristics with normal stem cells, i.e., self-renewal and differentiation potential, suggesting that they can drive cancer progression. Consequently, targeting CSCs to prevent tumor growth or regrowth might offer a chance to lead the fight against cancer. CSCs create their niche, a specific area within tissue with a unique microenvironment that sustains their vital functions. Interactions between CSCs and their niches play a critical role in regulating CSCs’ self-renewal and tumorigenesis. Differences observed in the frequency of CSCs, due to the phenotypic plasticity of many cancer cells, remain a challenge in cancer therapeutics, since CSCs can modulate their transcriptional activities into a more stem-like state to protect themselves from destruction. This plasticity represents an essential step for future therapeutic approaches. Regarding self-renewal, CSCs are modulated by the same molecular pathways found in normal stem cells, such as Wnt/β-catenin signaling, Notch signaling, and Hedgehog signaling. Another key characteristic of CSCs is their resistance to standard chemotherapy and radiotherapy treatments, due to their capacity to rest in a quiescent state. This review will analyze the primary mechanisms involved in CSC tumorigenesis, with particular attention to the roles of CSCs in tumor progression in benign and malignant diseases; and will examine future perspectives on the identification of new markers to better control tumorigenesis, as well as dissecting the metastasis process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063 · cited 2×
“CRISPR-Cas9 and RNA interference screening have also provided new insights into in vivo dependence and niche-cell interactions [131,132].”
BackgroundA framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“These findings are noteworthy, as they also hold implications for developing future anti-cancer therapies, as blocking these signals causes the cells to undergo the non-CSC to CSC transition [94].”
BackgroundWnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 1×
“the transcriptional activation of p21/WAF1, binding the cyclin E/Cdk2 and cyclin D/Cdk4 complexes to cause G1 cell cycle arrest [64,65].”
BackgroundExosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Molecular regulation of stem cell quiescence
Cheung, T. H., & Rando, T. A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3591 · Cited by 1,148 · cited 1×
“Quiescent stem cells can respond to stimuli from their niche by activating molecular and transcriptional mechanisms to enter the cell cycle [53].”
BackgroundCancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007 · cited 1×
“However, there is still a significant gap in targeting CSCs, as we still lack a specific or even a superficial marker that may be more suitable for future targeting of these cells [32,33].”
BackgroundSingle-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992 · cited 1×
“Single-cell sequencing efforts and multiregional tumor studies have defined the compositions of different intratumoral cells [134].”
BackgroundLactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940 · cited 1×
“This results in the enhanced production of metabolic acids, such as lactic acid, and acidification of the microenvironment, promoting CSC-like phenotypes [90,91].”
BackgroundZhou, W., Ke, S. Q., Huang, Z., Flavahan, W., Fang, X., Paul, J., Wu, L., Sloan, A. E., McLendon, R. E., Li, X., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3090 · Cited by 940
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870 · cited 1×
“In addition, dormant cells can evade detection by NK cells through repression of NK activation ligands, and are likely subject to surveillance by the adaptive immune system, which can maintain tumor cells in a dormant state through the actions of IFNγ [76,77].”
BackgroundMetastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.02.025 · Cited by 791 · cited 1×
“In addition, dormant cells can evade detection by NK cells through repression of NK activation ligands, and are likely subject to surveillance by the adaptive immune system, which can maintain tumor cells in a dormant state through the actions of IFNγ [76,77].”
BackgroundImayoshi, I., Sakamoto, M., Yamaguchi, M., Mori, K., & Kageyama, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4987-09.2010 · Cited by 716
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693 · cited 1×
“, subjected to hypoxic conditions [92,93].”
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
Liu, T., Zhou, L., Li, D., Andl, T., & Zhang, Y. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00060 · Cited by 446
Poltavets, V., Kochetkova, M., Pitson, S. M., & Samuel, M. S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00431 · Cited by 377
Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style
Merrell, A. J., & Stanger, B. Z. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.24 · Cited by 369
Horizontal Gene Transfer: From Evolutionary Flexibility to Disease Progression
Emamalipour, M., Seidi, K., Zununi Vahed, S., Jahanban-Esfahlan, A., Jaymand, M., Majdi, H., Amoozgar, Z., Chitkushev, L. T., Javaheri, T., Jahanban-Esfahlan, R., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00229 · Cited by 198 · cited 1×
“Genomes of evolving cells are subjected to higher plasticity than most conserved cells, and tumor cells must continually reinvent themselves to propagate in the recipient organism [202].”
BackgroundDownregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo
Gaur, A. B., Holbeck, S. L., Colburn, N. H., & Israel, M. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor033 · Cited by 180 · cited 1×
“A study of engineered exosomes containing miRNA (particularly miR-21) show they effectively downregulated target genes PDCD4 and RECK of the miR-21 in glioma cell lines [274].”
BackgroundWitt, A. E., Lee, C.-W., Lee, T. I., Azzam, D. J., Wang, B., Caslini, C., Petrocca, F., Grosso, J., Jones, M., Cohick, E. B., et al. (2017) · Oncogene · doi:10.1038/onc.2016.337 · Cited by 172
Thrombospondin 1 and Its Diverse Roles as a Regulator of Extracellular Matrix in Fibrotic Disease
Murphy-Ullrich, J. E. (2019) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155419851103 · Cited by 104 · cited 1×
“Thrombospondin-1 (TSP1), present in the basement membrane surrounding mature blood vessels, also promotes quiescence [75].”
BackgroundKim, E., Cheng, Y., Bolton-Gillespie, E., Cai, X., Ma, C., Tarangelo, A., Le, L., Jambhekar, M., Raman, P., Hayer, K. E., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160719 · Cited by 18
Cited by
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Cancer cells show evolving behavior of recurrence, dormancy, and drug resistance even after using conventional treatments (surgery, chemotherapy, etc.) mostly contributed by vicious cancer stem cells (CSCs) [7, 8].”
BackgroundMetabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35
Metadata
- Authors
- Aramini, B., Masciale, V., Grisendi, G., Bertolini, F., Maur, M., Guaitoli, G., Chrystel, I., Morandi, U., Stella, F., Dominici, M., & Haider, K. H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-02-15
- Volume
- 14
- Issue
- 4
- Pages
- 976
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4212911150
- Cited by
- 145
- References
- 31
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.